newsfilter
← Latest News
GlobeNewswire·

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

–Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients– –Expect to initiate ENLIGHTEN-Cirrhosis trial this quarter in MASH